Advertisement

Stealth Peptides Inc. of Newton Centre has enrolled the first of what it hopes to be 300 patients in its Phase 2 clinical trial to study the ability of its compound, Bendavia, to limit damage suffered in a heart attack.

SOURCE

Advertisement
Advertisement